Misinformation about the new anti-HIV injection, lenacapavir (brand name Sunlenca), is circulating on social media, with false claims about its safety and efficacy. As of May 2026, lenacapavir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection. It is not a vaccine but a capsid inhibitor that blocks the HIV virus's replication.
Recent posts have falsely claimed that lenacapavir causes severe side effects or is ineffective. However, clinical trials, including the CAPELLA study, showed that 83% of participants achieved viral suppression (HIV RNA <50 copies/mL) at week 26. Common side effects include nausea and injection site reactions, but serious adverse events were rare and comparable to placebo.
Another myth suggests that lenacapavir can replace all other HIV medications. In reality, it is used in combination with other antiretroviral drugs, as per FDA guidelines. It is administered as a subcutaneous injection every six months, offering a convenient option for patients with limited treatment options.
Health experts urge the public to verify information from reliable sources like the FDA or the World Health Organization (WHO). As of May 2026, no evidence supports claims that lenacapavir is dangerous or ineffective when used as prescribed.
